Selected publications of the first funding period at a glance

PIs of CRC1479 are first or last author and CRC1479 funding is indicated in the acknowledgement.

Vinnakota JM et al. Nature Cancer 2024 doi: 10.1038/s43018-024-00764-7
Schmitt M et al. Nature 2022 doi: 10.1038/s41586-022-05426-1
Masuda T et al. Nature 2022 doi: 10.1038/s41586-022-04596-2
Friedrich M et al. Nature Cancer 2022 doi: 10.1038/s43018-021-00201-z
Sankowski R et al. Nature Medicine 2024 doi: 10.1038/s41591-023-02673-1
Wertheimer T et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01755-7
Maas-Bauer K et al. Nature Commun. 2024 doi: 10.1038/s41467-024-44703-7
Velasco Cárdenas RM et al. Nature Immunol 2023 doi: 10.1038/s41590-023-01658
Zhang YW et al. Nature Cell Biology 2022 doi: 10.1038/s41556-022-00931-x
Ho J et al. Blood 2022 doi: 10.1182/blood.2022016082
Rückert T et al. Sci Transl Med. 2022 doi: 10.1126/scitranslmed.abp9675.
Talvard-Balland N et al. J Clin Invest. 2024 doi: 10.1172/JCI177460.
Denk D et al. Immunity 2022 doi: 10.1016/j.immuni.2022.09.014
Schmidt D et al. Cancer Res. 2024 doi: 10.1158/0008-5472.CAN-23-3553
Nicolas AM et al. Cancer Cell. 2022 doi: 10.1016/j.ccell.2022.01.004
Grünwald BT et al. Cell 2021 doi: 10.1016/j.cell.2021.09.022.
Zhang Z et al. Nature Immunol. 2025 doi: 10.1038/s41590-024-02027-0.
Braun L et al. Cancer Cell. 2025 doi: 10.1016/j.ccell.2025.01.004.
Vinnakota JM et al. Sci Transl Med. 2024 doi: 10.1126/scitranslmed.adj9672.
Edwards-Hicks J et al. Nature Immunol. 2023 doi: 10.1038/s41590-023-01419.
Saller BS et al. Immunity 2024 doi: 10.1016/j.immuni.2024.10.012.
Heim K et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01928-4.
Gallage S et al. Cell Metab. 2024 doi: 10.1016/j.cmet.2024.04.015.
Denk D et al. Immunity 2025 doi: 10.1016/j.immuni.2025.02.005
Gorantla SP et al. Nature Commun 2025 doi: 10.1038/s41467-025-60019-6

Publications based on CRC1479 funding

Peighambari A, Huang H, Metzger P, Adlesic M, Zodel K, Schäfer S, Seidel P, Braun LM, Hülsdünker J, Melchinger W, Follo M, Ku M, Haug S, Li Y, Köttgen A, Schell C, von Elverfeldt D, Reichardt W, Zeiser R, Heikenwalder M, Höfflin R, Börries M, Frew IJ. Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance. Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1.

Gorantla SP, Rassner M, Crossley KA, Müller TA, Poggio T, Khaja Saleem S, Kleinfelder H, Gambheer SMM, Endres C, Schaberg S, Schmidt D, Prince G, Gonzalez-Menendez I, Bentrop D, Trittler R, Rylova S, Pfeifer D, Andrieux G, Quintanilla-Martinez L, Illert AL, von Bubnoff N, Zeiser R, Duyster J. Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling. Nat Commun. 2025 May 24;16(1):4833. doi: 10.1038/s41467-025-60019-6.

Ho NHJG, Talvard-Balland N, Köhler N, Zeiser R. Immune Escape of Acute Myeloid Leukemia after Transplantation. Blood Cancer Discov. 2025 May 5;6(3):168-181. doi: 10.1158/2643-3230.BCD-24-0063.

Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel LF, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess DA, Frew I, Burk AC, Holzmüller V, Grimbacher B, Michonneau D, Andrieux G, Socié G, Kolter J, Börries M, Follo M, Blaeschke F, Sevenich L, Prinz M, Zeiser R, Vinnakota JM. AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling. Blood Adv. 2025 Mar 31:bloodadvances.2024015000. doi: 10.1182/bloodadvances.2024015000. Epub ahead of print.

Denk D, Ramakrishnan M, Conche C, Pallangyo C, Pesic M, Ceteci F, Kennel KB, Kirisözü AC, Engel E, Mohs K, Ritter B, Pardo AM, Özkurt E, Hildebrand F, Waisman A, Arkan MC, Greten FR. IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis. Immunity. 2025 Mar 11;58(3):701-715.e8. doi: 10.1016/j.immuni.2025.02.005. Epub 2025 Feb 28.

Rodov A, Baniadam H, Zeiser R, Amit I, Yosef N, Wertheimer T, Ingelfinger F. Towards the Next Generation of Data-Driven Therapeutics Using Spatially Resolved Single-Cell Technologies and Generative AI. Eur J Immunol. 2025 Feb;55(2):e202451234. doi: 10.1002/eji.202451234.

Müller M, Zodel K, Abhari BA, Cuomo F, Nizamuddin S, Metzger P, Boerries M, Timmers HTM, Frew IJ. KDM5C and KDM5D mutations have different consequences in clear cell renal cell carcinoma cells. Commun Biol. 2025 Feb 15;8(1):244. doi: 10.1038/s42003-025-07695-8.

Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, Zeiser R. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell. 2025 Feb 10;43(2):269-291.e19. doi: 10.1016/j.ccell.2025.01.004.

Scherer N, Fässler D, Borisov O, Cheng Y, Schlosser P, Wuttke M, Haug S, Li Y, Telkämper F, Patil S, Meiselbach H, Wong C, Berger U, Sekula P, Hoppmann A, Schultheiss UT, Mozaffari S, Xi Y, Graham R, Schmidts M, Köttgen M, Oefner PJ, Knauf F, Eckardt KU, Grünert SC, Estrada K, Thiele I, Hertel J, Köttgen A. Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet. 2025 Jan;57(1):193-205. doi: 10.1038/s41588-024-01965-7. Epub 2025 Jan 2.

Catalano A, Haas LS, Zodel K, Adlesic M, Cuomo F, Peighambari A, Metzger P, Huang H, Haug S, Köttgen A, Köhler N, Boerries M, Frew IJ. Mutations in tumor suppressor genes Vhl and Rassf1a cause DNA damage, chromosomal instability and induce gene expression changes characteristic of clear cell renal cell carcinoma. Kidney Int. 2024 Dec 24:S0085-2538(24)00912-8. doi: 10.1016/j.kint.2024.12.003. Epub ahead of print.

Zhang Z, Langenbach M, Sagar S, Fetsch V, Stritzker J, Severa E, Meng K, Winkler F, Rana N, Zoldan K, Godbole I, Solis S, Weber JS, Rafei-Shamsabadi D, Lehr S, Diehl R, Venhoff AC, Voll RE, Buettner N, Neumann-Haefelin C, Boettler T, Hofmann M, Boerries M, Meiss F, Zeiser R, Thimme R, Herati RS, Bengsch B. Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1⁺CD8⁺ T cells. Nat Immunol. 2024 Dec 19. doi: 10.1038/s41590-024-02027-0. Epub ahead of print.

D’Avanzo C, Blaeschke F, Lysandrou M, Ingelfinger F, Zeiser R. Advances in cell therapy: progress and challenges in hematological and solid tumors. Trends Pharmacol Sci. 2024 Dec;45(12):1119-1134. doi: 10.1016/j.tips.2024.10.016. Epub 2024 Nov 27.

Saller BS, Wöhrle S, Fischer L, Dufossez C, Ingerl IL, Kessler S, Mateo-Tortola M, Gorka O, Lange F, Cheng Y, Neuwirt E, Marada A, Koentges C, Urban C, Aktories P, Reuther P, Giese S, Kirschnek S, Mayer C, Pilic J, Falquez-Medina H, Oelgeklaus A, Deepagan VG, Shojaee F, Zimmermann JA, Weber D, Tai YH, Crois A, Ciminski K, Peyronnet R, Brandenburg KS, Wu G, Baumeister R, Heimbucher T, Rizzi M, Riedel D, Helmstädter M, Buescher J, Neumann K, Misgeld T, Kerschensteiner M, Walentek P, Kreutz C, Maurer U, Rambold AS, Vince JE, Edlich F, Malli R, Häcker G, Kierdorf K, Meisinger C, Köttgen A, Jakobs S, Weber ANR, Schwemmle M, Groß CJ, Groß O. Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation. Immunity. 2024 Nov 15:S1074-7613(24)00492-8. doi: 10.1016/j.immuni.2024.10.012. Epub ahead of print.

Giesler S, Riemer R, Lowinus T, Zeiser R. Immune-mediated colitis after immune checkpoint inhibitor therapy. Trends Mol Med. 2024 Oct 29:S1471-4914(24)00266-1. doi: 10.1016/j.molmed.2024.09.009. Epub ahead of print.

Heim K, Sagar, Sogukpinar Ö, Llewellyn-Lacey S, Price DA, Emmerich F, Kraft ARM, Cornberg M, Kielbassa S, Knolle P, Wohlleber D, Bengsch B, Boettler T, Neumann-Haefelin C, Thimme R, Hofmann M. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol. 2024 Sep;25(9):1650-1662. doi: 10.1038/s41590-024-01928-4. Epub 2024 Aug 28. PMID: 39198634.

Zeiser R. Introduction to a review series on oncogenic signaling and immune evasion in hematologic malignancies. Blood. 2024 Jun 27;143(26):2679. doi: 10.1182/blood.2024023825.

Talvard-Balland N, Braun LM, Dixon KO, Zwick M, Engel H, Hartmann A, Duquesne S, Penter L, Andrieux G, Rindlisbacher LS, Acerbis A, Ehmann J, Köllerer C, Ansuinelli M, Rettig A, Moschallski K, Apostolova P, Brummer T, Illert AL, Schramm MA, Cheng Y, Köttgen A, Duyster J, Menssen HD, Ritz J, Blazar BR, Boerries M, Schmitt Graeff A, Sariipek N, van Galen P, Buescher JM, Cabezas-Wallscheid N, Pahl HL, Pearce EL, Soiffer RJ, Wu CJ, Vago L, Becher B, Köhler N, Wertheimer T, Kuchroo VK, Zeiser R. Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. J Clin Invest. 2024 Jun 25:e177460. doi: 10.1172/JCI177460. Epub ahead of print.

Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, Staehle HF, Vinnakota JM, Duquesne S, Mozaffari Jovein M, Pfeifer D, Becker H, Blazar BR, Zähringer A, Duyster J, Brummer T, Boerries M, Baumeister J, Shoumariyeh K, Li J, Green AR, Heidel FH, Tirosh I, Pahl HL, Leimkühler N, Köhler N, de Toledo MAS, Koschmieder S, Zeiser R. Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF-β Expression and Regulatory T Cell Expansion in the Bone Marrow Microenvironment. Cancer Res. 2024 Jun 17. doi: 10.1158/0008-5472.CAN-23-3553. Epub ahead of print.

Vinnakota JM, Adams RC, Athanassopoulos D, Schmidt D, Biavasco F, Zähringer A, Erny D, Schwabenland M, Langenbach M, Wenger V, Salié H, Cook J, Mossad O, Andrieux G, Dersch R, Rauer S, Duquesne S, Monaco G, Wolf P, Blank T, Häne P, Greter M, Becher B, Henneke P, Pfeifer D, Blazar BR, Duyster J, Boerries M, Köhler N, Chhatbar CM, Bengsch B, Prinz M, Zeiser R. Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation. Sci Transl Med. 2024 Jun 12;16(751):eadj9672. doi: 10.1126/scitranslmed.adj9672. Epub 2024 Jun 12. PMID: 38865481.

Chen YB, Mohty M, Zeiser R, Teshima T, Jamy O, Maertens J, Purtill D, Chen J, Cao H, Rossiter G, Jansson J, Fløisand Y. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial. Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03016-4. Epub ahead of print.

Selected publications of the first funding period at a glance

Publications based on CRC1479 funding

Contact